Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 12Breast Neoplasms 7Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Relapsed Solid Tumors 1Refractory Solid Tumors 1Prostatic Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1

Interventions

verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Temozolomide 1Sorafenib 1Irinotecan 1Interleukin-27 1Erlotinib Hydrochloride 1Azurin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory Solid Tumors × eribulin × Clear all
NCT06006273 2026-05-20

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡